PowerGen Solar I in Italy: The Breach Is Cured, Cash Flow Still Depends on Conditions
PowerGen Solar I completed a EUR 5.6 million equity injection to cure the Italian covenant breach, but the next read is still about cash timing. The GSE receipt suspension and a mostly conditional asset sale keep the proof point in actual collections, not formal compliance.
Italy no longer looks like an open covenant event, but it still does not look like a clean cash source. PowerGen Solar I completed an approximately EUR 5.6 million equity injection in April to cure the breach measured as of December 31, 2025, and the financial statements state that as of March 31, 2026 the company was in compliance with the financial covenants under its financing agreements and bonds. That closes the immediate legal issue, but it does not close the economic question that made Italy important in the first place: whether the assets there can release cash after debt service without equity injections, reserve draws, or delayed receipts. Two post-quarter disclosures keep the answer conditional. The planned sale of an Italian asset carries total consideration of up to EUR 4.9 million, but only EUR 200 thousand is paid as an advance, while the rest depends on semiannual payments, performance and improvement mechanisms over several years. At the same time, from March 31, 2026, GSE temporarily suspended receipts for several Italian facilities, even though the company expects the amounts to be paid retroactively once the deficiencies are fixed. The updated read is therefore narrower than the original breach story: the risk is no longer only whether the covenant can be cured, but whether the cash that should replace cure injections arrives on time and with enough certainty.
The Injection Cured the Breach, but Did Not Build New Headroom
In leveraged renewable-energy projects, covenants, debt service reserve accounts and interest hedges are normal parts of the financing structure. What is less normal is a sequence in which the company draws roughly EUR 6 million from a DSRF in June 2025 for scheduled debt service, misses the historical ADSCR threshold of 1.05 at two test dates, and cures the event through equity injections: roughly EUR 2 million in December 2025 and roughly EUR 5.6 million in April 2026. That closes a legal event, but it still does not prove that the cash problem has disappeared.
The loan balance under the Italian financing agreement was approximately NIS 207 million at the report date. The company also states that, relative to the amounts drawn to date, it hedged approximately 95% of its interest-rate exposure, above the minimum 75% requirement. So the Italian pressure does not look like a simple unhedged-rate story. It looks more like a project-cash-coverage story, especially when the cure comes from equity flowing in rather than surplus cash coming out of the assets.
The relevant cash frame here is all-in cash flexibility after the real cash uses: debt service, reserve use, equity cure injections, suspended receipts, and proceeds from asset disposals. This is not a normalized cash-generation calculation for the Italian portfolio in a representative year. The company itself presents a stronger representative-year view for Italy, with estimated revenue of NIS 67-69 million and cash flow after debt service of NIS 17-19 million, but that estimate depends on operational, engineering and financing improvement and on electricity-price forecasts. The first quarter does not yet prove that this path is already open.
Two Post-Quarter Disclosures Keep Cash Conditional
In the first quarter, the Italian segment generated NIS 9.9 million of revenue, down from NIS 11.7 million in the comparable quarter, and recorded a segment loss of NIS 6.8 million after NIS 6.4 million of net finance expenses. This is not the covenant metric itself, but it explains why an equity-funded cure is not enough to turn Italy into a cash-flow strength. To reduce the risk, the next evidence needs to be timely collections, less cash pushed into the structure, and disposals that produce more certain cash.
| Event | What Has Already Happened | Why Cash Is Still Conditional |
|---|---|---|
| Covenant cure | In April the company completed an approximately EUR 5.6 million equity injection to cure the December 31, 2025 breach | No updated Italian ADSCR headroom was disclosed after the cure, so the next proof point is compliance without another injection and without another reserve draw |
| Italian asset sale | The board approved an outline to sell the asset company for total consideration of up to approximately EUR 4.9 million | The advance is EUR 200 thousand, while the rest depends on semiannual payments through 2031 and contingent consideration mechanisms through 2037 |
| GSE receipt delay | From March 31, 2026, receipts for several facilities were temporarily suspended, mostly for the subsidy component | The company expects completion within several weeks and retroactive payment, but the outcome still depends on technical fixes, third parties and Italian regulatory requirements |
The planned Italian sale matters because it can bring in cash and reduce exposure, but the consideration structure does not look like a simple disposal. An AS IS sale with a small advance and payments tied to the buyer's future performance and improvements means a large part of the value remains future-dependent. The balance sheet already shows NIS 24.9 million of assets held for sale related to Italy and NIS 7.3 million of liabilities held for sale, but the reported disposal does not turn that whole amount into immediate cash.
The GSE receipt delay is also not presented by the company as a liquidity crisis. The company says the deficiencies were resolved in most facilities, that completion is expected within several weeks, and that the delay is not expected to have a material effect on cash flow, operations, or debt repayment during the suspension period. That is an important counterweight. Still, after a covenant breach that was cured with equity, every delay in Italian receipts carries more weight, because the question is no longer only whether revenue will eventually be recorded, but whether its timing protects the debt structure without outside support.
The Next Read Is Actual Collection
This is not an immediate liquidity problem for the whole company. At quarter-end, the company had approximately NIS 132 million of consolidated cash and cash equivalents, and approximately NIS 89 million at the separate-company level. The board also points to signed credit facilities, expected equity extraction under the Storage 2 financing agreement, revenue from operating assets, and access to debt capital markets. The conclusion is therefore not that Italy endangers near-term repayment, but that it still defines the quality of cash flow and the accessibility of value to bondholders and shareholders.
The next proof point should be narrow and concrete: actual resumption of GSE receipts, preferably with full retroactive payment, the next Italian ADSCR test passed without another equity injection and without another DSRF use, and progress in the asset sale so that consideration starts becoming less conditional. If those three things happen, the Italian cure will look like a transition point. If they do not, formal covenant compliance alone will not prove that the Italian assets are generating genuinely free cash.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.